48 results about "Fovea centralis" patented technology

Methods for analyzing retinal tomography maps to detect patterns of optic nerve diseases such as glaucoma, optic neuritis, anterior ischemic optic neuropathy are disclosed in this invention. The areas of mapping include the macula centered on the fovea, and the region centered on the optic nerve head. The retinal layers that are analyzed include the nerve fiber, ganglion cell, inner plexiform and inner nuclear layers and their combinations. The overall retinal thickness can also be analyzed. Pattern analysis are applied to the maps to create single parameter for diagnosis and progression analysis of glaucoma and optic neuropathy.

ABSTRACT OF THE DISCLOSURE The newly discovered retinal ganglion cell photoreceptor melanopsin absent in the central fovea of the eye but distributed throughout the remaining human retinal body provides both non-visual biological / physiological input inducing circadian entrainment, and visual input affecting perceived brightness; this perceived brightness is not the object brightness commonly associated with luminance and perceived color of an object in central view, but the perception of brightness of a whole space or task background. Discussed are improvements to circadian lighting systems based on melanopsin stimulation whereby ambient and / or device background lighting may be temporally tuned over a range of prescribed color temperatures from a first subset of lighting having a higher melanopic content to a second subset of lighting having a lower melanopic content or vice versa in accordance with a desired circadian cycle, and in a manner where net light output is of a constant perceived brightness and color throughout temporal tuning.

Lenses and methods are provided for improving peripheral and / or central vision for patients who suffer from certain retinal conditions that reduce central vision or patients who have undergone cataract surgery. The lens is configured to improve vision by having an optic configured to focus light incident along a direction parallel to an optical axis at the fovea in order to produce a functional foveal image. The optic is configured to focus light incident on the patient's eye at an oblique angle with respect to the optical axis at a peripheral retinal location disposed at a distance from the fovea, the peripheral retinal location having an eccentricity between −30 degrees and 30 degrees. The image quality at the peripheral retinal location is improved by reducing at least one optical aberration at the peripheral retinal location. The method for improving vision utilizes ocular measurements to iteratively adjust the shape factor of the lens to reduce peripheral refractive errors.

A prism prescription value acquisition system that includes a calculation part for numerically transforming a fixation disparity amount (unit: angle), which indicates a degree at which the visual axis is shifted from the central fovea of the retina when a subject conducts visual fixation of a target, into a prism prescription value by multiplying the fixation disparity amount by a coefficient when the fixation disparity amount is within ±4 minutes. Herein, the prism prescription value is calculated according to the following equation: APver=kver*FDver, APhor=khor*FDhor providing that each of coefficients khor and kver satisfies the following conditions: 0.3≦kver≦0.7, 1.4≦khor≦2.0.

Intraocular injection of adeno-associated viral (AAV) vectors has been an evident route for delivering gene drugs into the retina. Currently, the vectors need to be injected into the subretinal spacein order to provide gene delivery to cones. In this approach, gene delivery is limited to cells that contact the local "bleb" of injected fluid. Furthermore, retinal detachment that occurs during subretinal injections is a concern in eyes with retinal degeneration. Here, the inventors establish several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea with supporting studies in mouse models, human induced pluripotent stem cell-derived organoids, post-mortem human retinal explants and living macaques. They show that an AAV9variant provides efficient foveal cone transduction when injected into the subretinal space several millimeters away from the fovea, without detaching this delicate region. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Accordingly, the present invention relates to method of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein asset forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12.

An intraocular lens system comprising a single lens comprising two optical surfaces selected to maintain image quality at the foveal centre whilst reducing image aberration at preferred retinal locus locations outside of the fovea region.

Provides neuroprotective therapy for glaucoma, including the generation of micropulsed laser beams with parameters and characteristics, including pulse length, power, and duty cycle, selected to produce a therapeutic effect without visually visible laser lesions or damage to the retina tissue damage. Laser beams are applied to the retinal tissue and / or foveal tissue of eyes with or at risk of glaucoma to produce therapeutic effects on the retinal tissue and / or foveal tissue exposed to the laser beam without destroying or permanently Damage retinal tissue and / or foveal tissue, and improve the function or condition of the optic nerve cells and / or retinal ganglion cells of the eye.